Hepatopulmonary syndrome associated with long-term use of ado-trastuzumab emtansine (T-DM1) for treatment of HER2-positive metastatic breast cancer - a case report and series
As T-DM1 is approved for use in the management of early-stage operable and advanced breast cancer, awareness of HPS as a potential complication of long-term administration of T-DM1 is necessary. The emergence of dyspnea alone or combined with low oxygen saturation and signs of hypoxemia (clubbing or elevated hemoglobin) should raise clinical suspicion and prompt evaluation for HPS. Cancer care team members should be vigilant regarding the potential for new and serious side effects associated with novel targeted therapies, which may emerge years beyond initial regulatory approval.
Authors
- Patrick S. Kamath (ORCID: https://orcid.org/0000-0002-7888-1165)
- Adham K. Alkurashi (ORCID: https://orcid.org/0000-0001-7856-7048)
- Tufia C. Haddad (ORCID: https://orcid.org/0000-0001-8226-3581)
- Vaibhav Ahluwalia
- Alexandra Higgins (ORCID: https://orcid.org/0000-0001-6626-0700)
- Ciara C. O’Sullivan (ORCID: https://orcid.org/0000-0001-6069-9800)
- Vivek Iyer (ORCID: https://orcid.org/0000-0001-6441-9319)
- Jodi L. Taraba (ORCID: https://orcid.org/0000-0001-6200-9332)
- Paul M. McKie (ORCID: https://orcid.org/0000-0003-0019-4768)
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.3389/fonc.2024.1434492
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28